Here are four insights:
1. PhRMA backs Ms. Clinton’s plan to cap a patient’s share of a drug’s cost at $250 each month.
2. PhRMA, however, strongly opposes Ms. Clinton’s plan to fight high drug costs.
3. While Clinton’s proposal does not impact a drug’s full price, it does force the insurance company to pay a larger portion of the cost.
4. PhRMA CEO Stephen Ubl said the group understands patients often face obstacles accessing their medicine due to high prices.
More articles on quality & infection control:
Pennsylvania Patient Safety Authority names new executive director — 5 highlights
Senate pushing more medical bills forward: 5 notes
Community Health Worker model yields better outcomes for patients in outpatient settings — 4 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
